Yakoot Mostafa, Abdel Salaam M
Green Clinic, Alexandria, Egypt.
Arq Gastroenterol. 2009 Jul-Sep;46(3):179-82. doi: 10.1590/s0004-28032009000300007.
To determine the efficacy and safety of 'healer' cream as monotherapy in the treatment of acute and chronic anal fissure.
A prospective, randomized, single blinded, comparative trial.
Sixty patients suffering from anal fissure were included in the study. Patients were randomly divided into three groups: group A: treated with 'healer' local cream application 3 times daily; group B: treated with nitroglycerine 0.25% local cream 3 times daily; group C: treated with a lidocaine 2% cream applied locally 3 times daily. All the followings were followed up and compared between groups. (1) Visual pain analogue score after defecation; (2) severity of straining and discomfort during defecation; (3) frequency of ulcer healed at 30 days; (4) any side effects or complications.
The pain scoring after defecation was significantly reduced in the three treatment groups. The group treated with 'healer' isosorbide-di-nitrate showed the greatest reduction of the visual pain analogue score median from 9 before treatment to 3 & 1 after 10 and 20 days respectively, while the median visual pain analogue score in group B treated with nitroglycerine cream was 9 reduced to 4 & 2 after 10 and 20 days respectively, and the median visual pain analogue score in lidocaine group only dropped from 9 to 6 and 4, respectively. The reduction of both pain scoring and defecation scoring with 'healer' was statistically significantly greater than the other two treatments by Kruskal-Wallis test, P<0.001. The number of patients experiencing complete relief and passing stools easily after 10 days was significantly higher in 'healer' group, by Pearson Chi square = 22.94, P<0.001. After 30 days, the fissures were healed in 18 (90%) of 20 patients in the 'healer' group and in 12 (60%) of 20 in the nitroglycerin group, while only 6 (30%) of patients treated with lidocaine cream had their fissures healed by the 30 days treatment. Chi square = 15 (P = 0.001).
'Healer' is a promising effective and safe line of treatment in acute and chronic anal fissure. The characteristic pharmacokinetics of isosorbide-di-nitrate leads to a better effect than nitroglycerin in healing (more prolonged action). Also the less fast absorption than nitroglycerin leading to a smoother dose concentration curve, may be the cause that headache is less frequent and less severe in 'healer' treatment versus nitroglycerin.
确定“Healer”乳膏作为单一疗法治疗急慢性肛裂的疗效和安全性。
一项前瞻性、随机、单盲、对照试验。
60例肛裂患者纳入本研究。患者被随机分为三组:A组:每日3次局部应用“Healer”乳膏;B组:每日3次局部应用0.25%硝酸甘油乳膏;C组:每日3次局部应用2%利多卡因乳膏。对所有患者进行随访,并比较以下各项:(1)排便后视觉模拟疼痛评分;(2)排便时用力和不适的严重程度;(3)30天时溃疡愈合的频率;(4)任何副作用或并发症。
三个治疗组排便后的疼痛评分均显著降低。使用“Healer”异山梨醇二硝酸酯治疗的组视觉模拟疼痛评分中位数降低幅度最大,从治疗前的9分别降至10天和20天后的3和1,而使用硝酸甘油乳膏治疗的B组视觉模拟疼痛评分中位数分别从9降至10天和20天后的4和2,利多卡因组视觉模拟疼痛评分中位数仅从9降至6和4。通过Kruskal-Wallis检验,“Healer”组在疼痛评分和排便评分降低方面均显著大于其他两种治疗方法,P<0.001。“Healer”组在10天后完全缓解且排便轻松的患者数量显著更高,Pearson卡方检验=22.94,P<0.001。30天后,“Healer”组20例患者中有18例(90%)肛裂愈合,硝酸甘油组20例中有12例(60%)愈合,而使用利多卡因乳膏治疗的患者在30天治疗后只有6例(30%)肛裂愈合。卡方检验=15(P = 0.001)。
“Healer”是治疗急慢性肛裂的一种有前景的有效且安全的治疗方法。异山梨醇二硝酸酯独特的药代动力学导致其在愈合方面比硝酸甘油效果更好(作用更持久)。而且与硝酸甘油相比,其吸收速度较慢导致剂量浓度曲线更平滑,这可能是“Healer”治疗相对于硝酸甘油治疗头痛频率更低、程度更轻的原因。